EA200401331A1 - Фармацевтическая препаративная форма, включающая мелатонин - Google Patents

Фармацевтическая препаративная форма, включающая мелатонин

Info

Publication number
EA200401331A1
EA200401331A1 EA200401331A EA200401331A EA200401331A1 EA 200401331 A1 EA200401331 A1 EA 200401331A1 EA 200401331 A EA200401331 A EA 200401331A EA 200401331 A EA200401331 A EA 200401331A EA 200401331 A1 EA200401331 A1 EA 200401331A1
Authority
EA
Eurasian Patent Office
Prior art keywords
preparative form
melatonin
including melatonin
pharmaceutical preparative
pharmaceutical
Prior art date
Application number
EA200401331A
Other languages
English (en)
Other versions
EA007954B1 (ru
Inventor
Нава Зисапел
Original Assignee
Ньюрим Фармасьютикалз (1991) Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29227410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200401331(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ньюрим Фармасьютикалз (1991) Лтд. filed Critical Ньюрим Фармасьютикалз (1991) Лтд.
Publication of EA200401331A1 publication Critical patent/EA200401331A1/ru
Publication of EA007954B1 publication Critical patent/EA007954B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

Кратковременное потенцирование не барбитуратных и не бензодиазепиновых снотворных средств осуществляется посредством применения мелатонина.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200401331A 2002-04-28 2003-03-20 Фармацевтическая препаративная форма, включающая мелатонин EA007954B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL149377A IL149377A (en) 2002-04-28 2002-04-28 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
PCT/IL2003/000240 WO2003086352A1 (en) 2002-04-08 2003-03-20 Pharmaceutical formulation comprising melatonin

Publications (2)

Publication Number Publication Date
EA200401331A1 true EA200401331A1 (ru) 2005-04-28
EA007954B1 EA007954B1 (ru) 2007-02-27

Family

ID=29227410

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401331A EA007954B1 (ru) 2002-04-28 2003-03-20 Фармацевтическая препаративная форма, включающая мелатонин

Country Status (29)

Country Link
US (1) US20050175692A1 (ru)
EP (1) EP1494650B1 (ru)
JP (1) JP2005527583A (ru)
KR (1) KR101000624B1 (ru)
CN (1) CN100386070C (ru)
AR (1) AR039232A1 (ru)
AT (1) ATE507831T1 (ru)
AU (1) AU2003227304B2 (ru)
BR (1) BR0308762A (ru)
CA (1) CA2477516C (ru)
DE (1) DE60336999D1 (ru)
DK (1) DK1494650T3 (ru)
EA (1) EA007954B1 (ru)
ES (1) ES2366116T3 (ru)
GT (1) GT200300064A (ru)
HN (1) HN2003000115A (ru)
IL (1) IL149377A (ru)
IS (1) IS2858B (ru)
MX (1) MXPA04009893A (ru)
NO (1) NO332525B1 (ru)
NZ (1) NZ536298A (ru)
PE (1) PE20040161A1 (ru)
PL (1) PL209922B1 (ru)
PT (1) PT1494650E (ru)
TW (1) TW200305404A (ru)
UA (1) UA86924C2 (ru)
UY (1) UY27753A1 (ru)
WO (1) WO2003086352A1 (ru)
ZA (1) ZA200407563B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1696959A2 (en) * 2003-12-24 2006-09-06 Sepracor, Inc. Melatonin combination therapy for improving sleep quality
TW200626137A (en) * 2004-12-13 2006-08-01 Takeda Pharmaceuticals Co Preventive or therapeutic agent for sleep disorder
US20060198872A1 (en) * 2005-03-07 2006-09-07 Chioma Ikonte Plant based dietary supplement for improving the duration and quality of sleep
KR20070070307A (ko) * 2005-08-24 2007-07-04 에스에스 세야쿠 가부시키 가이샤 수면 개선 의약 조성물
CN1299680C (zh) * 2005-08-29 2007-02-14 陈彦方 一种治疗失眠的黑白制剂
AR056076A1 (es) * 2005-09-20 2007-09-19 Takeda Pharmaceutical Agente profilactico o terapeutico para el desorden de sueno
CN102018681A (zh) * 2010-12-10 2011-04-20 荣港生技医药科技（北京）有限公司 一种美乐托宁缓释剂、其制备方法及其应用
US9532952B2 (en) * 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
EP2570126B1 (en) 2011-09-16 2014-03-26 Darius Rassoulian Use of melatonin for treating acute alcohol intoxication
SG11201903829PA (en) * 2016-10-31 2019-05-30 Neurim Pharma 1991 Melatonin mini-tablets and method of manufacturing the same
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
CN109364031A (zh) * 2018-10-07 2019-02-22 威海贯标信息科技有限公司 一种盐酸曲唑酮片剂组合物
EP4090315A1 (en) * 2020-01-17 2022-11-23 Société des Produits Nestlé S.A. Dosage form with sustained release melatonin pellets

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600723A (en) * 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
US5707652A (en) * 1990-12-04 1998-01-13 State Of Oregon Methods of treating circadian rhythm phase disorders
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
FR2718020B1 (fr) * 1994-04-01 1996-05-31 Biotec Centre Sa Composition galénique mucoadhésive hétérofonctionnelle.
MD1716C2 (ru) * 1995-02-01 2002-02-28 Neurim Pharmaceuticals (1991) Ltd. Применение мелатонина для лечения пациентов с бензодиазепиновой зависимостью
ES2175350T5 (es) * 1996-03-08 2008-12-16 Takeda Pharmaceutical Company Limited Compuestos triciclicos que tienen afinidad de union a receptores de melatonina, su produccion y uso.
AU2583397A (en) * 1996-04-10 1997-10-29 Chronorx, Llc Unit dosage forms, containing magnesium, vitamin c, vitamin e, folate and selenium, for treatment of vasoconstriction and related conditions
ATE265209T1 (de) * 1996-07-17 2004-05-15 Merck & Co Inc Änderung des zirkadischen rhythmus mit nicht- peptidischen neurokinin-1 rezeptor antagonisten
EP1100508B8 (en) * 1998-06-09 2004-01-07 Takeda Chemical Industries, Ltd. Pharmaceutical combination comprising a tricyclic compound and at least one of zolpidem, zopiclone and brotizolam for treating or preventing sleep disorders
CN1131030C (zh) * 1999-03-18 2003-12-17 胡秀云 一种由褪黑素和安定制成的调节睡眠的组合物
AU3910700A (en) 1999-03-22 2000-10-09 Immugen Pharmaceuticals, Inc. Treatment of immune diseases
IL144900A (en) * 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs

Also Published As

Publication number Publication date
JP2005527583A (ja) 2005-09-15
HN2003000115A (es) 2004-04-20
MXPA04009893A (es) 2005-06-17
PL372867A1 (en) 2005-08-08
TW200305404A (en) 2003-11-01
EP1494650B1 (en) 2011-05-04
IS2858B (is) 2013-12-15
DE60336999D1 (de) 2011-06-16
ES2366116T3 (es) 2011-10-17
EP1494650A4 (en) 2006-07-12
WO2003086352A1 (en) 2003-10-23
ATE507831T1 (de) 2011-05-15
EA007954B1 (ru) 2007-02-27
AU2003227304A1 (en) 2003-10-27
GT200300064A (es) 2003-11-26
IL149377A (en) 2012-10-31
ZA200407563B (en) 2005-11-30
AU2003227304A2 (en) 2005-04-14
IL149377A0 (en) 2009-02-11
UY27753A1 (es) 2003-05-30
DK1494650T3 (da) 2011-08-08
IS7492A (is) 2004-10-07
UA86924C2 (ru) 2009-06-10
NO332525B1 (no) 2012-10-08
HK1075616A1 (zh) 2005-12-23
EP1494650A1 (en) 2005-01-12
CN100386070C (zh) 2008-05-07
NO20043576L (no) 2004-12-22
CN1646098A (zh) 2005-07-27
NZ536298A (en) 2008-09-26
PL209922B1 (pl) 2011-11-30
PT1494650E (pt) 2011-08-18
CA2477516A1 (en) 2003-10-23
KR101000624B1 (ko) 2010-12-10
KR20040101406A (ko) 2004-12-02
BR0308762A (pt) 2005-01-11
US20050175692A1 (en) 2005-08-11
PE20040161A1 (es) 2004-03-22
AU2003227304B2 (en) 2007-12-06
AR039232A1 (es) 2005-02-09
CA2477516C (en) 2012-12-11

Similar Documents

Publication Publication Date Title
EA200401331A1 (ru) Фармацевтическая препаративная форма, включающая мелатонин
PA8539901A1 (es) Novedosa sal de succinato de o-desmetil-venlafaxina
EA200301213A1 (ru) Лиганды рецепторов 5-ht и их применение
ATE461217T1 (de) Glp-1-verbindungen
EA200500520A1 (ru) Пуриновые соединения и их применение в качестве лигандов каннабиноидных рецепторов
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
ATE320436T1 (de) Dimere pyrrolobenzodiazepine
ECSP045491A (es) Nueva sal formiato de o-desmetil venlafaxina
ATE509634T1 (de) Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel
ATE387435T1 (de) Substituirte benzosulfonamide als potenzierungsmittel von glutamatrezeptoren
PA8637601A1 (es) Compuestos moduladores de la actividad de c-kit y usos de los mismos
EA199900981A1 (ru) Лептин как ингибитор пролиферации опухолевых клеток
DE60332705D1 (de) Kolbenring mit spritzbeschichtung
EA200300450A1 (ru) Фармацевтические растворы соединений модафинила
UY27902A1 (es) Derivados aldehido de polietilenglicol
EA200401621A1 (ru) Модуляторы сск-1 рецепторов
EA200300727A1 (ru) Производные 2h-1-бензопирана, способы их получения и их фармацевтические композиции
DE60308368D1 (de) Camptothecine mit modifiziertem lactonring
BR0316544A (pt) Compostos calcilìticos
DE60335610D1 (de) Neoplasma-spezifische antikörper und deren verwendungen
EA200500609A1 (ru) Ассоциация лиганда рецепторов, активированных пролифератором пероксисом, и антиоксидантного агента и фармацевтические композиции, которые их содержат
DE60043922D1 (de) Halbleiteranordnung mit konfiguration mittels kodierung von benachbarten anschlussflächen
EA200501299A1 (ru) Замещенные производные анилина
EA200001050A1 (ru) Малеат пароксетина
EA200400877A1 (ru) 2'-гало-3',5'-диалкоксифен-1'-илимино-2-имидазолидиновые производные и их применение для лечения недержания мочи

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM